Monitoring
Review patients as clinically indicated to monitor for signs and symptoms of disease progression, and to evaluate for indications of cytoreductive therapy.[37]
Monitor blood count regularly in all patients, including asymptomatic patients and those in a steady state after starting treatment.
Patients treated with hydroxyurea should have complete hemogram and platelet count every 2 weeks during the first 2 months, then every month, and, when patients are responding in a steady state, every 3 months.[72]
For those taking peginterferon alfa-2a, platelet count and complete hemogram must be recorded every week during the first month of treatment, every 2 weeks during the second month, then every month, and, when patients are responding in a steady state, every 3 to 4 months.[72]
Use of this content is subject to our disclaimer